Podcasts about topiramate

Un nouvel épisode du Pharmascope est disponible! Dans ce 145e épisode, Nicolas, Isabelle et Olivier essaient de ne pas trop vous faire trembler en revisitant une vieille littérature et un problème incommodant : le tremblement essentiel. Les objectifs pour cet épisode sont les suivants: Expliquer l'épidémiologie, la présentation clinique et l'évaluation du tremblement essentiel. Conseiller des mesures non-pharmacologiques pour aider les personnes avec un tremblement essentiel. Discuter des bénéfices et des désavantages associés aux principaux traitements pharmacologiques du tremblement essentiel. Ressources pertinentes en lien avec l'épisode  Shanker V. Essential tremor: diagnosis and management. BMJ. 2019 Aug 5;366:14485 Welton T, Cardoso F, Carr JA, Chan LL, Deuschl G, Jankovic J, Tan EK. Essential tremor. Nat Rev Dis Primers. 2021 Nov 11;7(1):83. Baizabal-Carvallo JF, Morgan JC. Drug-induced tremor, clinical features, diagnostic approach and management. J Neurol Sci. 2022 Apr 15;435:120192 Ferreira JJ et coll. MDS Task Force on Tremor and the MDS Evidence Based Medicine Committee. MDS evidence-based review of treatments for essential tremor. Mov Disord. 2019 Jul;34(7):950-958. Serrano-Dueñas M. Use of primidone in low doses (250 mg/day) versus high doses (750 mg/day) in the management of essential tremor. Double-blind comparative study with one-year follow-up. Parkinsonism Relat Disord. 2003 Oct;10(1):29-33. Bruno E, Nicoletti A, Quattrocchi G, Allegra R, Filippini G, Colosimo C, Zappia M. Topiramate for essential tremor. Cochrane Database Syst Rev. 2017 Apr 14;4(4):CD009683. Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, Koller WC, Schwarzman L, Wu SC, Hulihan JF; Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology. 2006 Mar 14;66(5):672-7. Bruno E, Nicoletti A, Quattrocchi G, Filippini G, Colosimo C, Zappia M. Pregabalin for essential tremor. Cochrane Database Syst Rev. 2016 Oct 20;10(10):CD009682 Bruno E, Nicoletti A, Quattrocchi G, Filippini G, Zappia M, Colosimo C. Alprazolam for essential tremor. Cochrane Database Syst Rev. 2015 Dec 6;2015(12):CD009681. Marques A et coll. Trial of Botulinum Toxin for Isolated or Essential Head Tremor. N Engl J Med. 2023 Nov 9;389(19):1753-1765. Yetimalar Y, Irtman G, Kurt T, Başoğlu M. Olanzapine versus propranolol in essential tremor. Clin Neurol Neurosurg. 2005 Dec;108(1):32-5.

Topiramate is not as well-known as an anticonvulsant as some of the other drugs that we have discussed. However, it has a potential role at least as an adjunctive medication and so we talk about what we know of its efficacy and safety in this episode. It seems that this is a safe drug at least in dogs and in the future may even have a role in the treatment of status epilepticus - so listen in and see what you think.

Today, we look at the nerve pain medication, Topiramate....

What is the link between artificial nighttime outdoor light, air pollution, and stroke? Find out about this and more in today's PeerDirect Medical News Podcast.

Beginning with a discussion on the evolution of these medications, Dr. Bikman emphasizes their significance in combating obesity-related health issues. He proceeds to analyze the mechanisms of popular weight loss drugs, such as Orlistat, Phentermine, and the combination of Phentermine with Topiramate, elucidating how each functions to aid weight loss.While highlighting the benefits, Dr. Bikman doesn't shy away from detailing the potential side effects, ensuring a comprehensive understanding for the audience. Moreover, he shares an intriguing scientific fact regarding lactate's role in fat metabolism, adding depth to the discussion. Throughout, Dr. Bikman maintains a balance between scientific evidence and personal insight, fostering an engaging and informative session.In discussing liraglutide's mechanism of action, Dr. Bikman reveals its role as a GLP-1 receptor agonist, mimicking the actions of the incretin GLP-1. He then previews next week's class dedicated to incretins and their use in weight loss drugs, including medications like wegovy and ozempic.Liraglutide primarily promotes weight loss by reducing gastric emptying, leading to prolonged feelings of fullness and decreased appetite. Additionally, it inhibits glucagon, lowering blood glucose levels and subsequently increasing metabolic rate and fat burning. Dr. Bikman notes common side effects such as gastrointestinal discomfort and hints at potential risks of thyroid tumors associated with GLP-1 agonists.Ben transitions to discussing semaglutide, another GLP-1 receptor agonist, and its similar effects on weight loss and side effects, including the possibility of ileus. He also touches on metformin's off-label use for weight loss, its mechanisms involving AMPK activation and ATP inhibition, and its potential interference with exercise-induced mitochondrial benefits.Learn more at: Insulin IQ Hosted on Acast. See acast.com/privacy for more information.

We're taking a short summer break, but we'll be back in September with brand-new episodes. Can't wait? Join our Kashlak family at patreon.com/curbsiders for access to twice-monthly bonus episodes… there are already 9 of them available to feed your brain hole! Yummy! Obesity treatment has been around since the 1950s but we've been underutilizing it for far too long! Not only that, we've been thinking about obesity the wrong way for decades. Join us with Dr. Fatima Cody Stanford (@AskDrFatima) of Massachusetts General Hospital as we reframe our approach to this disease and learn tips on prescribing  older,  but still very effective, medications used to treat obesity.  Free CME for this episode at curbsiders.vcuhealth.org Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Credits Producer, Writer, Show Notes, Infographics, Cover Art: Isabel Valdez, PA-C Show Notes, Infographics: Maddison McLellan Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Monee Amin, MD Executive Producer: Beth Garbitelli Showrunner: Matthew Watto MD, FACP Editor: Clair Morgan of nodderly.com Guest: Fatima Cody Stanford, MD  Sponsor: Locumstory Get a comprehensive view of Locumstory at locumstory.com Sponsor: Babbel .Get 55% off your Babbel subscription at Babbel.com/curb. Rules and restrictions apply.  CME Partner: VCU Health CEThe Curbsiders are partnering with VCU Health Continuing Education to offer FREE continuing education credits for physicians and other healthcare professionals. Visit curbsiders.vcuhealth.org and search for this episode to claim credit.The Curbsiders are partnering with VCU Health Continuing Education to offer FREE continuing education credits for physicians and other healthcare professionals. Visit curbsiders.vcuhealth.org. Show Segments Intro, disclaimer, guest bio Guest one-liner by Dr. Fatima Cody Stanford Case from Kashlak  Guidelines for treatment  Getting the history and discussing weight goals The Care Team:  Dietician, Behavioral Specialist, Provider Medications: Phentermine, Topiramate, Bupropion, Naltrexone Obesity treatment in pregnancy Referring to bariatric surgery Take home points Outro

This is the 28th podcast episode for the Psychiatric Medication Podcast Series. Series Description: Current literature indicates that podcasts can be an effective educational format to reach health professionals across the continuum of medical education, addressing a myriad of topics pertinent to providers. This episode serves as an overview of Topiramate/Topamax. This podcast season is the second released by East Carolina University's Office of Continuing Medical Education and may be beneficial for physicians, residents, fellows, nurse practitioners, physician assistants, and nurses. This podcast season is comprised of approximately 30 episodes, each focusing on different psychiatric medications for the non-psychiatric provider. Those tuning into the podcast's second season will receive a primer on the "bread and butter" behavioral health medications for primary care: antidepressants, antipsychotics, and mood stabilizers. Episodes will be released weekly on Wednesdays.Irene Pastis, MD & Daniel Majarwitz, MD

Dr. Iyad Alnahhas interviews Drs. Maria Jose Contreras-Zarate and Diana Cittelly about their recent manuscript entitled: "Short-term topiramate treatment prevents radiation-induced cytotoxic edema in preclinical models of breast-cancer brain metastasis", published online in Neuro-Oncology in April 2023. Read Paper

Have you had a patient ask you about using Topiramate to treat their alcohol use disorder? Or maybe you've heard a colleague talk about it, but don't know much about it? In this episode we review the use of the medication topiramate in treating alcohol use disorder. Spoiler alert! This may be practice changing!

Episode 106: Weight Loss Meds. Anti-obesity medications are FDA-approved drugs to support your patient's efforts to lose weight. It is important for primary care providers to learn about these medications to continue fighting against obesity in our communities.Introduction: Obesity is a chronic disease.By Hector Arreaza, MD. Obesity has all the characteristics of a chronic disease. Let's use our imagination and think about a patient with hypertension, for example. Let's imagine you are the doctor or Mr. Lee. He is 45 years old and his blood pressure has been persistently high, around 150/100, even after lifestyle modifications. You decide to start chlorthalidone 25 mg and Mr. Lee takes chlorthalidone every day. Four weeks later you see Mr. Lee again and you review his labs with him. He has normal renal function and normal electrolytes. His blood pressure is now 119/75. He is feeling great and reports no side effects to chlorthalidone. Would you stop the medication at this time? Think about it. The most obvious answer is NO, you will not stop chlorthalidone. Today you will listen to a discussion about anti-obesity medications, common indications, contraindications, cautions, and more. We will learn that obesity requires chronic treatment with medications just like any other chronic disease. I hope you enjoy it.This is the Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California. Our program is affiliated with UCLA, and it's sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.___________________________Weight Loss Meds. By Sapna Patel, MS4; and Danish Khalid, MS$. Ross University School of Medicine. Moderated by Hector Arreaza, MD. S: Hello and welcome back to our nutrition series! If you haven't already listened to our previous episodes, pause this and make sure to give them a listen. We have talked about physical activity, meal plans, and intermittent fasting. Today we are going to talk about the clinical management of obesity, specifically the pharmacotherapy that is used. We will divide these drugs into drugs that reduce food intake primarily acting on the CNS, drugs that reduce fat absorption and medications that are associated with weight gain. D: Can anyone who is considered obese take medications to help them lose weight? Pharmacotherapy should be considered if the patient will be taking the medication in conjunction with the overall weight management program, including changes in eating habits, increased physical activity, and realistic expectations of the medication therapy. Adjuvant pharmacologic treatments should be considered for patients with a BMI >30 kg/m2 or with BMI >27 kg/m2 who have concomitant obesity related diseases. A: You are going to find doctors who are pretty much against anti-obesity drugs, but that's not my case.  S: Drugs that reduce food intake primarily acting on the CNS: Let's start with Phentermine and other sympathomimetic drugs A: Phentermine has been in the market over 60 years and it is well tolerated by most patients. It is effective, expect 5-8 lbs weight loss a month when taken with dietary changes and increased physical activity. The weight loss happens mostly the first 3-6 months when you take anti-obesity medications. S: One of the longest clinical trials of the drugs in this group lasted 36 weeks and compared placebo treatment to treatment with continuous phentermine and intermittent phentermine. Both the continuous and intermittent phentermine therapy produced more weight loss than placebo. D: Other options are Phentermine and topiramate ER which is known as  “Qsymia”. These drugs combine a catecholamine releaser and anticonvulsant respectively.  Topiramate is currently approved by the USFDA as an anticonvulsant for treatment of epilepsy and for prophylaxis of migraine headaches. Weight loss was seen as an unintentional side effect during clinical trials for epilepsy.The mechanism responsible for this is thought to be mediated through the modulation of GABA receptors, inhibition of carbonic anhydrase and antagonism of glutamate to reduce food intake The common adverse effects include cognitive impairment, paresthesia, and increased risk for kidney stones. Topiramate is also a teratogenic drug, so patients need to be in a good birth control to take it. It causes cleft palate in the fetus.The 2 phase-III trials called EQUIP and CONQUER, both 1 year randomized  placebo-controlled double-blinded clinical trials, 3 different strengths of a once-a day formulation were tested: full strength dose (15 mg of phentermine and 92 mg of topiramate ER), mid-dose (7.5mg of phentermine and 92 mg topiramate ER) and low dose (3.75mg of phentermine and 23 mg of topiramate ER). Subjects  randomized to the full strength dose in EQUIP and CONQUER trials lost an average of 10.9% and 9.8% body weight in 1 year compared to 1.6% and 1.2% loss for placebo subjects respectively. Significant improvement in fasting glucose, insulin, Hemoglobin A1C and lipid profile were seen.Due to the dose dependent side effects of the medications an initial dose of 3.75/23 mg is prescribed daily for the first 14 days then increased to 7.5/23mg daily. These patients should be re-evaluated after 3 months. If 3% weight loss is not achieved by that time, either discontinue or escalate the dose to 15/92mg for 12 weeks. S: Drugs that reduce fat absorption:Orlistat. What is orlistat? Well it's a selective inhibitor of pancreatic lipase that reduces the intestinal digestion of fat. The mean weight loss when compared to a placebo was 2.51kg at 6 months and 2.75kg at 12 months. A: It is one of the few anti-obesity medications approved to be used in children 12 years and older. D: GLP-1 Receptor Agonist (-glutide): Semaglutide and Liraglutide - Only two that have been approved for treatment of obesity. A 20-week randomized trial, comparing Liraglutide, placebo, and orlistat, showed that patients assigned to liraglutide lost significantly more weight than those assigned to both. When compared to placebo, those on liraglutide lost a mean weight loss of 2.8 kg. Whereas compared to orlistat lost an average of 5.8kg, however this was on the higher doses of liraglutide. A 56-weeks trial, comparing liraglutide with placebo, showed a mean weight loss was significantly greater in the liraglutide group (8.0 kg vs 2.6 kg). Furthermore, those who initially lost weight with diet and exercise, a greater proportion of those taking liraglutide maintained the weight loss.  Similarly, clinical trials favored semaglutide, with a weight loss greater in the semaglutide group versus placebo. For both, weight loss occurred in patients with and without diabetes. Note: Semaglutide: once a week. Helps induce weight loss. Liraglutide: daily.  A: We dedicated a whole episode on Semaglutide and another whole episode on Tirzepatide. Tirzepatide (dual agonist: GLP-1 and GIP) seems promising for weight loss and it is likely to be approved soon for obesity treatment. So, when do we discontinue anti-obesity medications? We can ask the same question for other chronic diseases: When do we stop medication for hypertension or diabetes? When we have a patient is unable to keep their weight off, we can't see him/her as someone who has lost their motivation to keep their weight off. Really what's happened is that their hormones have changed in a way that is promoting weight gain and it's very hard to lose weight. We should be at the patient's side to fight it off. Conclusion: Now we conclude our episode number 106 “Weight Loss Meds.” Phentermine is the most widely used anti-obesity medication. It is a stimulant, and it is a safe and effective medication for most patients who are fighting obesity. Make sure you learn the contraindication, side effects, and precautions when you prescribe it. Also, learn about other meds that are very effective, including GLP-1 receptor agonists, and your patients will thank you. This week we thank Hector Arreaza, Danish Khalid, and Sapna Patel. Audio by Sheila Toro.Thanks for listening to Rio Bravo qWeek Podcast. If you have any feedback, contact us by email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References: Perreault, L., Apovian, C. (2021). Obesity in adults: Overview of management. Pi-Sunyer,  F.X., Seres, D., & Kunins, L. (Eds.) Uptodate. Available from: https://www-uptodate-com.rossuniversity.idm.oclc.org/contents/obesity-in-adults-overview-of-management?search=weight%20loss%20medications&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2 Perreault, L. (2022). Obesity in adults: Drug therapy. Pi-Sunyer,  F.X., & Kunins, L. (Eds.) Uptodate. Available from: https://www-uptodate-com.rossuniversity.idm.oclc.org/contents/obesity-in-adults-drug-therapy?search=weight%20loss%20medications&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1 Dungan, K., DeSantis, A. (2022) Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus. Nathan, D.M., & Mulder, J.E. (Eds.) Uptodate. Available from: https://www-uptodate-com.rossuniversity.idm.oclc.org/contents/glucagon-like-peptide-1-based-therapies-for-the-treatment-of-type-2-diabetes-mellitus?search=glp%201%20receptor%20agonists&source=search_result&selectedTitle=2~97&usage_type=default&display_rank=1 Perreault, L., Bessesen, D. (2022). Obesity in adults: Etiologies and risk factors. Pi-Sunyer,  F.X., & Kunins, L. (Eds.) Uptodate. Available from: https://www-uptodate-com.rossuniversity.idm.oclc.org/contents/obesity-in-adults-etiologies-and-risk-factors?search=medication%20associated%20with%20weight%20gain§ionRank=1&usage_type=default&anchor=H1612312650&source=machineLearning&selectedTitle=1~150&display_rank=1#H1612312650. Royalty-free music used for this episode: Salsa Trap by Caslo, downloaded on July, 20, 2022 from https://freemusicarchive.org/music/caslo/caslo-vol-1/salsa-trap/. Space Orbit by Scott Holmes, downloaded on July, 20, 2022 from https://freemusicarchive.org/music/Scott_Holmes/.  

Not medical licensed advice . Always consult with your doctor:New Treatments For ObesityBMI: 25-30 : overweight  >30 ObeseWHO 2016 40% are over weight and 13% obese slightly higher in females . This is triple that in 1975UK 2019 House of Commons Library  40% are overweight and 30% obese higher in middle aged and elderly menNHS 2021: Children Obesity has gone up in 12 years from 19% to 25% The Surprising Link Between Chronic Inflammation & Obesity—Plus What You Can Do About ItMay 5th 2021Leptins are hormones produced by adipocytes that communicate with the hypothalamus to reduce eating. If you have too much leptin you become leptin resistant and do not stop eating. High leptin levels are also associated with  chronic inflammation.Conversely losing weight reduces systemic inflammation. REVIEW articleFront. Physiol., 29 January 2020Sec. Clinical and Translational PhysiologyChronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 DiabetesFrederika ZatteralThe key mediator of inflammation in obesity is the innate immune system cell the macrophage that can account for up to 40% of adipose tissue and it differentiates into a pro-inflammatory M1 macrophage setting up chronic inflammation.Obesity and Inflammation: A Vicious CycleDoes obesity cause inflammation or does inflammation lead to obesity?Jun 25, 2020Jennifer LutzObesity causes chronic inflammation via a chronic immune reaction initiated in the adipose tissue but inflammatory cells can go round the body. In addition gut inflammation may be a result also of the poor diet that led to the obesity.We know that obesity has tripled in the last 50 years such that 40% of the western world are obese. In fact 75% are prediabetic.Cardiovascular disease leading to cardiac disease and strokes, diabetes, cancer, depression, osteoarthritis all feed back and make it more likely you will continue to be obese.Higher adiposity and mental health: causal inference using Mendelian randomization Francesco Casanova,Jessica O'Loughlin,Susan Martin,Robin N Beaumont,Andrew R Wood,Edward R Watkins,Rachel M Freathy,Saskia P Hagenaars,Timothy M Frayling,Hanieh Yaghootkar... Show moreAuthor NotesHuman Molecular Genetics, Volume 30, Issue 24, 15 December 2021, Pages 2371–2382, There is a bidirectional relationship between depression and obesity.Genetic sorting showed that it is obesity per se and not the metabolic unhealthiness due to the obesity such as diabetes that leads to depression.That said diabetes from obesity causes depression although obesity itself causes systemic inflammation which is an independent risk factor for depression and cancer.There are also huge psychosocial effects of obesity on mood.Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal Of Medicine March 2021John P.H. Wilding,Once a week subcutaneous Semaglutide reduced weight by up to 20%Semaglutide is a GLP-1 agonist so suppresses Glucagon and increases insulin hence controlling blood sugar. It also slows gastric emptying  increasing satiety and acts on Receptors in the Arcuate Nucleus in the brain to increase satiety.It is already licensed to treat Type 2 diabetes.It also reduces the risk of cardiovascular complication in Type 2 diabetes and at a cellular level reverses atherogenesis. There is a question on worsening the risk of retinopathy.Other GLP-1 agonists : Liraglutide Setmelanotide.CpdFDA Approved Medication for treating ObesityPhentermine, diethylpropion,benzphetamine, phendimetrazine , Orlistat, Phentermine/topiramate Qsymia, Bupropion/naltrexone, Semaglitide, Liraglutide, setmelanotideCpd Phentermine-topiramate: First combination drug for obesityInt J Applied Med Res 2015Singh et alPhentermine is a centrally acting sympathomimetic that reduces appetite and topiramate enhances GABA ergic transmission reducing Dopamine Response to food.This combination causes up to 10% weight loss maintained in 50% for 2 years.The relationship between early weight loss and weight loss maintenance with naltrexone bupropion therapy.THe Lancet Discovery Science 2022Le Roux et alNaltrexone blocks opiate receptors and bupropion (wellbutrin/zyban) blocks reuptake of dopamine  -reward pathways- .and noradrenaline . Weight loss is maintained at 1 yearBoth medications enhance each other on feeding and satiety

Topiramate can cause psychosis, or treat psychosis; worsen cognition, or improve it; cause depression or… You get the point. A look at the paradoxical world of psychopharmacology.CME: Podcast CME Post-Tests are available using this subscription. If you have already enrolled in that program, please log in.Published On: 08/01/2022Duration: 14 minutes, 16 seconds

This episode discusses the evidence and benefits of topiramate and stimulant replacement therapy for cocaine use disorder. It also addresses the use of these medications when there are comorbidities, such as alcohol use disorder and ADHD.  Faculty: Andrew Saxon, M.D.  Hosts: Jessica Diaz, M.D. Learn more about Premium Membership here Earn 1 CME: Experimental Pharmacotherapies for Stimulant Use Disorder Topiramate and Methylphenidate for Cocaine Use Disorder and Its Comorbidities

How does Phentermine vs Topiramate vs Qsymia compare for weight loss? What are the differences and similarities? Here's how these three drugs compare in terms of side effects, cost, dosing, and how you can use them effectively!

Learn how to prescribe affordable, effective medications for obesity medicine! We discuss metformin, naltrexone, bupropion, phentermine, topiramate, GLP1 agonists, and how to counsel patients about the available weight loss modalities. Dr. Fatima Cody Stanford (@AskDrFatima) of Massachusetts General Hospital helps reframe our approach as she walks through these Obesity Medicine FAQs. Obesity treatment has been around since the 1950s but we've been underutilizing it for far too long! Claim free CME for this episode at curbsiders.vcuhealth.org! Episodes | Subscribe | Spotify | Swag! | Top Picks | Mailing List | thecurbsiders@gmail.com | Free CME! Credits Producer, Writer, Show Notes, Infographics, Cover Art: Isabel Valdez, PA-C Show Notes, Infographics: Maddison McLellan Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Monee Amin, MD Executive Producer: Beth Garbitelli Showrunner: Matthew Watto MD, FACP Editor: Clair Morgan of nodderly.com Guest: Fatima Cody Stanford, MD  Sponsor: ACP Join us in Chicago for internal medicine's premier educational meeting April 28-30, 2022! We'll be there in person. For the Early Bird discount: use code IM22CURB. Visit annualmeeting.acponline.org to learn more.  Sponsor: Grammarly Our listeners can get 20% off Grammarly Premium at grammarly.com/CURB Sponsor: MedMastery Listers are eligible for a lifetime 15% off discount on subscription if you go to https://www.medmastery.com/curbsiders! CME Partner: VCU Health CE The Curbsiders are partnering with VCU Health Continuing Education to offer FREE continuing education credits for physicians and other healthcare professionals. Visit curbsiders.vcuhealth.org and search for this episode to claim credit.  Show Segments Intro, disclaimer, guest bio Guest one-liner by Dr. Fatima Cody Stanford Case from Kashlak  Guidelines for treatment  Getting the history and discussing weight goals The Care Team:  Dietician, Behavioral Specialist, Provider Medications: Phentermine, Topiramate, Bupropion, Naltrexone Obesity treatment in pregnancy Referring to bariatric surgery Take home points Outro

HEALTH NEWS    May be worth adopting plant based diet to ease chronic migraine severity, say doctors Stony Brook University and University of Pennsylvania, November 22, 2021   Prescribed meds, elimination diet, yoga and meditation provided no or little symptom relief Boosting dark green leafy veg intake may be key It may be worth adopting a plant based diet, rich in dark green leafy vegetables, to ease the symptoms of chronic migraine, suggest doctors in the online journal BMJ Case Reports. The recommendation comes after they treated a man who had endured severe migraine headaches without aura for more than 12 years.  He had tried prescribed meds (Zolmitriptan and Topiramate); cutting out potential ‘trigger' foods, including chocolate, cheese, nuts, caffeine, and dried fruit; and yoga and meditation in a bid to blunt the severity and frequency of his headaches. Nothing had worked. His headaches were accompanied by sensitivity to light and sound, and nausea and vomiting. On a scale of 0–10, he scored the pain severity as 10–12 out of 10.  The report authors advised the man to adopt the Low Inflammatory Foods Everyday (LIFE) diet, a nutrient dense, whole food, plant-based diet. The LIFE diet includes eating at least five ounces by weight of raw or cooked dark green leafy vegetables every day, drinking one 32-ounce daily green LIFE smoothie, and limiting intake of whole grains, starchy vegetables, oils, and animal protein, particularly dairy and red meat. After 3 months his migraines stopped completely, and they haven't returned in 7.5 years.      Exercising at the start of fast can help people reach ketosis 3.5 hours faster: study Brigham Young University, November 24, 2021       Now a new Brigham Young University study published in the journal Medicine & Science in Sports & Exercise finds that exercising intensely at the start of a fast may help maximize health benefits of temporarily foregoing food. Ketosis occurs when the body runs out of glucose—its first, preferred fuel—and begins breaking down stored fat for energy, producing chemicals called ketones as a byproduct. In addition to being a healthy energy source for the brain and heart, ketones combat diseases like diabetes, cancer, Parkinson's and Alzheimer's. For the study, the researchers asked 20 healthy adults to complete two 36-hour fasts while staying hydrated. Each fast began after a standardized meal, the first fast starting without exercise and the other with a challenging treadmill workout.  Exercise made a big difference: when participants exercised, they reached ketosis on average three and a half hours earlier in the fast and produced 43% more BHB. The theory is that the initial exercise burns through a substantial amount of the body's glucose, prompting a quicker transition to ketosis. Without exercise, the participants hit ketosis about 20 to 24 hours into the fast. To calm your emotions, get 15 minutes alone University of Rochester, November 24, 2021 Being by yourself—even for just 15 minutes—may decrease your strong positive and negative emotions, and instead reduce stress and induce calm, a new study suggests. Lead researcher Thuy-vy Nguyen, a doctoral candidate in clinical and social sciences in psychology at the University of Rochester, together with the cofounders of self-determination theory, psychology professors Richard Ryan and Edward Deci, conclude that solitude can lead to relaxation and stress reduction—as long as people actively chose to be alone. In general, solitude, the research finds, has a lessening effect not only on arousing positive emotions but also strong negative emotions, ultimately leaving people calmer, more relaxed, less angry, and less anxious. The researchers define solitude as “a psychological experience of being alone without communications, stimuli, activities, or devices that might facilitate virtual communications such as text messaging or social media.”   Fermented tea could help protect the liver from high-fat diet damage   Tianjin University (China), November 30, 2021   Water extracts of a fermented tea, known as Pu-erh tea, could help to reduce oxidative stress and protect the liver against damage caused by a high fat diet, research in rats has found.   The study, published in Food Science and Human Wellness, investigated the potential of the polyphenol and theabrownin-rich fermented tea to protect the liver after previous studies linked the tea to a raft of health benefits.    “Pu-erh tea can be used as a potential healthy drink for prevention and/or treatment of fatty liver disease and many diseases associated with oxidative stress,” suggested Jing and colleagues.   After the trial, they found that the Pu-erh extract led to decreases in body weight, fat index, MDA and NOS levels. They suggested that these were linked to increases in hepatic T-SOD, CAT and GSH-Px activities. Furthermore, it was found that the extracts increased production of hepatic glycogen and the activity of PK, and reduced glucose levels, thus potentially protecting the liver from the diseases associated with type II diabetes.     Excessive media exposure to traumatic events could harm kids Florida International University, November 20, 2021 FIU scientists investigating the effects of hurricanes and other natural disasters on children's brain development previously found that increased exposure to media coverage of disasters led kids to have post-traumatic stress (PTS) symptoms regardless of physical proximity. A new follow-up study led by FIU psychologists Anthony Dick and Jonathan Comer confirmed those findings and also showed that individual differences in the response in a key brain region involved in detecting threats—the amygdala—predicted the degree to which viewing storm-related media coverage led children to develop PTS symptoms. "Children are among the most vulnerable individuals during disasters, because they are still developing a sense of security, and have little personal control over their environments," said Anthony Dick, psychology professor and researcher at the Center for Children and Families. "PTS can adversely affect long term health in children, but these findings will help us inform communities and families on how they can better prepare for and respond to disasters in ways that mitigate potential negative long-term mental health effects."   Adults with ADHD four times more likely to have generalized anxiety disorder         University of Toronto, November 20, 2021   A new nationally representative study published online in the Journal of Affective Disorders found that one in four adults aged 20-39 with attention deficit hyperactivity disorder (ADHD) had generalized anxiety disorder (GAD). Those with ADHD were four times more likely to have GAD at some point in their life, when compared to those without ADHD. Even after controlling for other relevant factors, including sociodemographics, adverse childhood experiences, and a lifetime history of substance use disorders and major depressive disorders, those with ADHD still had more than double the odds of GAD. "These findings underline how vulnerable adults with ADHD are to generalized anxiety disorders," says lead author Esme Fuller-Thomson, professor at the University of Toronto's Factor-Inwentash Faculty of Social Work and Director of the Institute for Life Course & Aging. "There are many studies linking adult ADHD to depression and suicidality, but less attention has been paid to generalized activity disorders and other adverse outcomes across the life course."

Dr. Roland Engelbrecht is a family physician in British Columbia, Canada, who has dedicated his medical practice to addiction treatment. He is also a member of the Canadian Alcohol Use Disorder Society, founded by Dr. Jeff Harries.The goals of CAUDS include educating the public about alcohol use disorder and how it is a medical condition that deserves compassion, not stigma. CAUDS also works to educate healthcare providers and the public about proven medical treatments that are effective in helping people to overcome alcohol addiction.While previous episodes on this podcast have focused on the use of naltrexone in treating alcohol use disorder, there are other medical treatments which can be helpful, in addition to naltrexone, or as an alternative for people who cannot tolerate naltrexone. There are also people who do not respond well to naltrexone, so adding additional medication can sometimes be helpful.Now, that medication assisted treatment of alcohol use disorder is becoming more commonplace, mainly as a harm reduction method in the form of The Sinclair Method, it is important that patients and their doctors understand that there are additional treatments available that can help to make their program more effective, if needed.I hope that this podcast episode is helpful in providing useful information to patients who can share it with their doctors, and for doctors who are looking for additional resources to offer their patients. For more information on the topics discussed in this episode, please visit http://www.cauds.org/, and please follow CAUDS on social media.Twitter handle: @cauds_orgFacebook page: https://www.facebook.com/caudsorgAlso, for more great podcast episodes and articles, please visit https://therehab.com and https://drleeds.com.

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Karl Doghramji, MD, professor of psychiatry and human behavior; professor of neurology; and medical director, Jefferson Sleep Disorders Center, at the Vickie and Jack Farber Institute for Neuroscience of Jefferson Health. He shared his perspective on the current state of care for sleep disorders, the impact of the pandemic on sleep in the US, and some of the recent advances in therapeutics and research. Episode Breakdown: 1:15 – The role of sleep in individuals' emotional and physical lives 5:40 – Current awareness about the health effects of poor sleep 8:15 – Clinical and commercial tools to measure sleep 10:45 – Recent advances in therapeutics for sleep disorders 15:20 – Tailoring specific therapies for specific patients 17:15 – Neurology News Minute 19:45 – Narcolepsy as a model for other sleep disorders 22:20 – Patient identification and differential diagnosis 25:40 – The sleep specialist's inclusion in the comprehensive care model 28:25 – Meeting the increasing demand for sleep specialists 30:40 – Sleep's role in dementia and cognition 33:50 – The state of sleep amid the COVID-19 pandemic The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Phase 3 PHOENIX Study of AMX0035 in ALS Gets Under Way FDA Approves First Oral Solution of Topiramate to Treat Epilepsy, Migraines Robert Califf, MD, Nominated by Biden Administration as Next FDA Commissioner Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

This week there's positive news for the COVID-19 oral antiviral candidate, Paxlovid; The CDC expands a recall for aromatherapy sprays connected to fatal cases of a rare tropical disease; The first eye drop to treat presbyopia is approved; An alternative to naloxone gets fast tracked; And a study compares the migraine treatments erenumab and topiramate. 

We ask the big questions: Is topiramate a drug or a sugar? Do you need to use the FDA-approved combo pill for weight loss? And which of its 13 off-label psychiatric uses are ready for clinical practice? Published On: 5/17/2021 Duration: 25 minutes, 58 seconds Got feedback? Take the podcast survey.  

On this episode of the Real Life Pharmacology Podcast, I cover topiramate pharmacology. Topiramate is indicated for migraine prevention, seizures, and weight loss which are the most common uses that I see this medication used for. Topiramate has carbonic anhydrase activity, so rarely, use of this drug may induce metabolic acidosis. By far, the most common patient complaint I get with the use of topiramate is that it causes cognitive slowing or impairment.

ANTI CONVULSANTS DRUGS (part 1) : 1. GABAPENTIN & PREGABALIN. 2. BARBITURATES (phenobarbital & primidone ). 3 . BENZODIAZEPINES ( CL+ AM) - clobazam , clonazepam, clorazepate ... “AM” - diazepam, midazolam , lorazepam : USED TO TREAT STATUS EPILEPSY 4. ETHOSUXIMIDE : treat ABSCENCE SEIZURE 5 . PHENYTOIN & FOSPHENYTOIN , purple glove syndrome . 6 . LAMOTRIGINE 7 . Lennox gastaut syndrome : RUFINAMIDE , VALPROATES , BENZODIAZEPINES, TOPIRAMATE

We always say that single positive studies need replication, and here comes one. In 2012 a randomized trial found that the combination of topiramate and adderall xr worked better than placebo at helping people with frequent cocaine use stay sober. This new study [Link] sought to replicate that, although it was by the same research group as the original─Columbia’s New York State Psychiatric Institute. The new addition is a larger study looked at 127 patients over 3 months. Published On: 8/8/20 Duration: 2 minutes, 16 seconds Got feedback? Take the podcast survey.

In this week's episode of the Spine & Nerve podcast, Dr. Brian Joves and Dr. Nicolas Karvelas begin a new journal club format to discuss multiple articles that have a similar theme. The goal of this series on the podcast is to summarize recent research, and provide a discussion of some key points in regards to potential impact on clinical care. In this week's podcast the doctors summarize and discuss three recent articles regarding medications for treatment of chronic pain. Please see References section below for the articles discussed in today's podcast. References: 1. Alberti P, et al. Topiramate prevents Oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity. Neuropharmacology. 2020. 2. Karin Bruun-Plesner, MD, Morten Rune Blichfeldt-Eckhardt, MD, PhD, Henrik Bjarke Vaegter, MSc, PhD, Joergen T Lauridsen, MSc, PhD, Kirstine Amris, MD, MedScD, Palle Toft, MD, PhD, MedScD. Low-Dose Naltrexone for the Treatment of Fibromyalgia: Investigation of Dose–Response Relationships. Pain Medicine. 2020. 3. Lynn Webster, MD, Jeffrey Gudin, MD, Robert B Raffa, PhD, Jay Kuchera, MD, Richard Rauck, MD, Jeffrey Fudin, PharmD, Jeremy Adler, DMSc, PA-C, Theresa Mallick-Searle, NP. Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion. Pain Medicine. 2020. Follow our practice on Facebook at Spine & Nerve Diagnostic Center. Please leave us a comment or review- these help us to improve and provide value to more people. This podcast is for information and educational purposes only, it is not meant to be medical advice. If anything discussed may pertain to you, please seek council with your healthcare provider. The views expressed are those of the individuals expressing them, they may not represent the views of Spine & Nerve.

Topiramate effectively treats migraine.

All my side effects from the past two and a half years and what are all the possible side effects of Topiramate. Remember to SEIZE THE DAY! I have lots of Epileptic Help Content you might be interested. If you are looking for EASY Seizure Prevention ON THE GO so that you can actually go to your favorite places without the worry of forgetting a thing, then make like a tree and leave this bio to go over to my link. https://youtu.be/9lP3kTDAK5s If you are looking for GUIDE For Epileptics: MOVIE THEATER so you know exactly which movies are gonna trigger you and how to prevent seizures at the theater then don't stop learning and click this link. https://youtu.be/xnSA-XaZJxY If you are looking for Dealing with DEATH & EPILEPTIC FAMILY Members then no worries friend, I got your back with this Question and answer. Click the link. https://youtu.be/kT9NJEeRdgI I am just your friendly neighborhood Makayla True, an Awkward Epileptic Girl since the age of ten months old who is making it in this world. Learning lifes mysteries one day at a time... Welcome to my journey of Epilepsy Advocacy, Pink Aesthetic Taken To Another Level, Sarcasm, Home Schooled Comedy, Food Addition In Real Lyfe, Challenges because YOLO , Geekiness, Makeup Learning, and EVERYTHING IN BETWEEN. SUBSCRIBE! Because 1 out of every 26 people will have a seizure by the end of their life. Most deaths in epileptics occur because of everyday situations. Would you want someone to know how to save YOU? Approx. 292,000,000 people currently are affected by seizures. Don't hesitate to HMU if you have any questions. Thanks to my wonderful friends I have reached 112k wonderful people! Don't forget to comment down below video ideas, "Officially Sweet Fam", or please share me with all your friends for a chance of me following you on one of my social medias. O.O My socials are at the following ~~~~~~~~~~~~~~~~~~~~ Snapchat: MakaylaTrue ~~~~~~~~~~~~~~~~~~~~ Instagram: MakaylaTrue OR https://www.instagram.com/MakaylaTrue/ ~~~~~~~~~~~~~~~~~~~~ Live.me: MakaylaTrueOfficial ~~~~~~~~~~~~~~~~~~~~ Bigo: MakaylaTrue ~~~~~~~~~~~~~~~~~~~~ TikTok: MakaylaTrue ~~~~~~~~~~~~~~~~~~~~ Twitter: BeTruelyMakayla OR https://twitter.com/BeTruelyMakayla ~~~~~~~~~~~~~~~~~~~~ Facebook: Makayla True OR https://fb.me/BeTruelyMakayla ~~~~~~~~~~~~~~~~~~~~ Patreon: https://www.patreon.com/makaylatrue ~~~~~~~~~~~~~~~~~~~~ Love y'all so much! Until next time MT Officially Sweet family! --- Send in a voice message: https://anchor.fm/makaylatrue/message

There was so much news this week it was hard to pick what to talk about, so we hit our favourite news sources to see what was what. Believe it or not fur trading is a thing again — and it's not just for haberdasheries anymore. From video game 'Red Dead Redemption 2', migraines, cutting weight for MMA, Vietnamese food, DoorDash vs. Skip the Dishes, Johnny Depp, the movie 'Spotlight', to Rick Mercer's well-deserved Lifetime Achievement Award, we cover all that and more. Oooohhhh Canada! LINKS FOUND IN THIS PODCAST Long and McQuade The New York Times The Globe and Mail The Sprawl Canada Goose Red Dead Redemption 2 The Hustle DoorDash Skip the Dishes Movie: Spotlight Pho Houz SPECIAL THANKS TO Emre Cords for the great music!

On today’s show, we will be discussing the results of Kenneka Jenkins autopsy and toxicology results including why the prescription drug topiramate was found in her system in therapeutic ranges when her family stated that she had not been prescribed this drug.  Topiramate is used for to prevent and control seizures (epilepsy). This medication is also used to prevent migraine headaches and to decrease how often you get them.  So then if she didn’t have any of this, why was it in her system in prescribed therapeutic ranges?  Plus the fact that the autopsy results showed her brain was swollen and that her blood alcohol level was 0.112, higher than the legal limit of 0.08 for driving under the influence.  We will explore the evidence and conspiracy theories surrounding the Kenneka Jenkins’ unfortunate yet suspicious demise.  Will we ever really know the truth? We will also be discussing the pros and cons of Faith-Based Initiatives which was implemented by former President George W. Bush by executive order in January 2001. The purpose and goal this initiative sought were to strengthen faith-based and community organizations and expand their capacity to provide federally funded social services. Was this goal accomplished?  What changes if any did these programs and organizations accomplish through this initiative.  We welcome your views and insight.  Come join us  Call in Number is (347) 838-8622 Showtime is 2pm central and 3pm Eastern time zones

In this podcast, Chip Lavie, MD, joins Todd Whitthorne to discuss Qsymia (formerly dubbed Qnexa), a new weight loss medication approved by the FDA that should be available by the end of this year. Dr. Lavie is triple board certified in internal medicine, cardiovascular diseases, and nuclear cardiology, and is a staff cardiologist at the Ochsner Heart and Vascular Institute in New Orleans and is medical director of cardiac rehabilitation and preventive cardiology at the Ochsner Clinic Foundation. Dr. Lavie's also an active researcher and is the author, or co-author of more than 600 medical publications. As a society we need additional tools to help those who are struggling with weight. Seventy percent of  Americans are overweight or obese, and the number of those who are morbidly obese continues to grow. The new weight loss medication, Qsymia, is a combination of the drugs phentermine and topiramate, and it's estimated that weight loss will be 7- to 10 percent. For most individuals, this amount of weight loss can dramatically improve health values, although the person might well still not be at an ideal weight. Dr. Lavie and Todd discuss the potential impact this new medication may have on the obesity epidemic.